These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 24447897)

  • 1. Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults.
    Hendricks KA; Wright ME; Shadomy SV; Bradley JS; Morrow MG; Pavia AT; Rubinstein E; Holty JE; Messonnier NE; Smith TL; Pesik N; Treadwell TA; Bower WA;
    Emerg Infect Dis; 2014 Feb; 20(2):. PubMed ID: 24447897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women.
    Meaney-Delman D; Zotti ME; Creanga AA; Misegades LK; Wako E; Treadwell TA; Messonnier NE; Jamieson DJ;
    Emerg Infect Dis; 2014 Feb; 20(2):. PubMed ID: 24457117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDC Guidelines for the Prevention and Treatment of Anthrax, 2023.
    Bower WA; Yu Y; Person MK; Parker CM; Kennedy JL; Sue D; Hesse EM; Cook R; Bradley J; Bulitta JB; Karchmer AW; Ward RM; Cato SG; Stephens KC; Hendricks KA
    MMWR Recomm Rep; 2023 Nov; 72(6):1-47. PubMed ID: 37963097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Framework and Medical Countermeasure Use During an Anthrax Mass-Casualty Incident.
    Bower WA; Hendricks K; Pillai S; Guarnizo J; Meaney-Delman D;
    MMWR Recomm Rep; 2015 Dec; 64(4):1-22. PubMed ID: 26632963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Review of Hospital Treatment Outcomes for Naturally Acquired and Bioterrorism-Related Anthrax, 1880-2018.
    Person MK; Cook R; Bradley JS; Hupert N; Bower WA; Hendricks K
    Clin Infect Dis; 2022 Oct; 75(Suppl 3):S392-S401. PubMed ID: 36251553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program.
    Martin SW; Tierney BC; Aranas A; Rosenstein NE; Franzke LH; Apicella L; Marano N; McNeil MM
    Pharmacoepidemiol Drug Saf; 2005 Jun; 14(6):393-401. PubMed ID: 15717323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Obiltoxaximab (Anthim) for inhalation anthrax.
    Med Lett Drugs Ther; 2018 Sep; 60(1555):150-151. PubMed ID: 30383733
    [No Abstract]   [Full Text] [Related]  

  • 8. Pediatric anthrax clinical management: executive summary.
    Bradley JS; Peacock G; Krug SE; Bower WA; Cohn AC; Meaney-Delman D; Pavia AT;
    Pediatrics; 2014 May; 133(5):940-2. PubMed ID: 24777221
    [No Abstract]   [Full Text] [Related]  

  • 9. Learning from the 2001 anthrax attacks: immunological characteristics.
    Hadler JL
    J Infect Dis; 2007 Jan; 195(2):163-4. PubMed ID: 17191158
    [No Abstract]   [Full Text] [Related]  

  • 10. Raxibacumab.
    Mazumdar S
    MAbs; 2009; 1(6):531-8. PubMed ID: 20068396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitoxin Use in the Prevention and Treatment of Anthrax Disease: A Systematic Review.
    Hesse EM; Godfred-Cato S; Bower WA
    Clin Infect Dis; 2022 Oct; 75(Suppl 3):S432-S440. PubMed ID: 36251559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serious adverse events among participants in the Centers for Disease Control and Prevention's Anthrax Vaccine and Antimicrobial Availability Program for persons at risk for bioterrorism-related inhalational anthrax.
    Tierney BC; Martin SW; Franzke LH; Marano N; Reissman DB; Louchart RD; Goff JA; Rosenstein NE; Sever JL; McNeil MM;
    Clin Infect Dis; 2003 Oct; 37(7):905-11. PubMed ID: 13130401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioterrorism watch. Anthrax aftermath: adverse drug reactions, vaccine controversy undercut CDC extended treatment offer.
    Evans G
    Hosp Peer Rev; 2002 Mar; 27(3):suppl 1-4. PubMed ID: 11905387
    [No Abstract]   [Full Text] [Related]  

  • 14. The US capitol bioterrorism anthrax exposures: clinical epidemiological and immunological characteristics.
    Doolan DL; Freilich DA; Brice GT; Burgess TH; Berzins MP; Bull RL; Graber NL; Dabbs JL; Shatney LL; Blazes DL; Bebris LM; Malone MF; Eisold JF; Mateczun AJ; Martin GJ
    J Infect Dis; 2007 Jan; 195(2):174-84. PubMed ID: 17191162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthrax. From bioweapons backwater to main attraction.
    Bohannon J
    Science; 2003 Apr; 300(5618):414-5. PubMed ID: 12702854
    [No Abstract]   [Full Text] [Related]  

  • 16. Antitoxin Treatment of Inhalation Anthrax: A Systematic Review.
    Huang E; Pillai SK; Bower WA; Hendricks KA; Guarnizo JT; Hoyle JD; Gorman SE; Boyer AE; Quinn CP; Meaney-Delman D
    Health Secur; 2015; 13(6):365-77. PubMed ID: 26690378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From the Centers for Disease Control and Prevention. Additional options for preventive treatment for exposed persons to inhalational anthrax.
    JAMA; 2002 Feb; 287(5):579. PubMed ID: 11838446
    [No Abstract]   [Full Text] [Related]  

  • 18. BioThrax and Anthrasil for anthrax.
    Med Lett Drugs Ther; 2016 May; 58(1494):62. PubMed ID: 27148924
    [No Abstract]   [Full Text] [Related]  

  • 19. A Review of the Efficacy of FDA-Approved
    Couse Z; Cui X; Li Y; Moayeri M; Leppla S; Eichacker PQ
    Toxins (Basel); 2021 Jan; 13(1):. PubMed ID: 33450877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obiltoxaximab Prevents Disseminated Bacillus anthracis Infection and Improves Survival during Pre- and Postexposure Prophylaxis in Animal Models of Inhalational Anthrax.
    Yamamoto BJ; Shadiack AM; Carpenter S; Sanford D; Henning LN; Gonzales N; O'Connor E; Casey LS; Serbina NV
    Antimicrob Agents Chemother; 2016 Oct; 60(10):5796-805. PubMed ID: 27431219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.